2021 ASH Annual Meeting: Plenary Abstract on ZUMA-7 Study, With Drs. Frederick Locke & Brad Kahl

Contributing Editors Drs. Frederick Locke and Brad Kahl discuss Dr. Locke's work on the ZUMA-7 Study, a plenary abstract that will be presented at the 2021 ASH Annual Meeting's Plenary Scientific session on Sunday, December 12.

Show Notes

In this installment of our 2021 ASH Annual Meeting Podcast series, Contributing Editor Dr. Brad Kahl has a conversation with Contributing Editor Dr. Frederick Locke about his work on one of the plenary abstracts that will be presented at the 2021 ASH Annual Meeting. The abstract presents an analysis of the ZUMA-7 trial of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma.
For coverage of the plenary scientific session, including this abstract and many other sessions, check www.ashpublications.org/ashnewsdaily throughout the meeting.       
Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/

What is The Hematologist?

The Hematologist is the member newsletter of American Society of Hematology (ASH). It is designed for the broad constituency of ASH, all working toward the ultimate goal of conquering blood diseases. The Hematologist updates readers about important developments in the field of hematology and highlights what ASH is doing for its members.